First-HD: a Phase III clinical research trial conducted in the U.S. and Canada of an investigational drug, SD-809ER led by Dr. Samuel Frank (Boston University School of Medicine) and Dr. Claudia Testa (Virginia Commonwealth University) to evaluate its safety, tolerability and effectiveness in reducing chorea. Dr. Frank provides an overview in this video. Visit here for more information.
CREST-E: A global, multi-center, clinical trial run in collaboration with Massachusetts General Hospital investigating the effects of creatine monohydrate on the progression of Huntington disease, led by Dr. Steven Hersch.
PREDICT-HD 2.0 - Observational research study for at-risk gene positive, pre-symptomatic, and gene negative tested individuals, with headquarters at the University of Iowa, under the leadership of Dr. Jane Paulsen.
On-going HSG Research Studies & Clinical Trials (ENROLLMENT COMPLETED)
Reach2HD - A clinical research trial investigating the effects of PBT2 on invidividuals with early to mid-stage Huntington disease, led by Ray Dorsey of Johns Hopkins University and Diana Rosas of Massachusetts General Hospital.
2CARE: A multi-center, randomized, double-blind, placebo-controlled trial led by Merit Cudkowicz, Michael McDermott, and Karl Kieburtz, assesing the effects of coenzyme Q10 on inviduals with mild-to-moderate Huntington disease.
PREQUEL: A clinical trial investigating the safety and tolerability of coenzyme Q10 for individuals with pre-manifest Huntington disease, led by Dr. Christopher Ross (John Hopkins University) and co-led by Dr. Kevin Biglan (University of Rochester).